Amgen-GSK OA-ANZBMS Clinical Grants Program 2015
GUIDE TO APPLICANTS
Thank you for your interest in the Amgen-GSK OA-ANZBMS Clinical Grants Program. The Program
offers opportunities for scientifically and/or medically qualified researchers to conduct high quality
clinical research that aims to:


Reduce the burden of osteoporotic fractures
Improve the clinical care and quality of life of people with osteoporosis and fractures
Please read the following information carefully before completing your application
APPLICANT ELIGIBILITY
Applicants to this program must:
 Hold current membership of ANZBMS
 Be employed by a university, hospital or academic research institution based in Australia or
New Zealand
 Have a recognised research or medical qualification
PROJECT ELIGIBILITY
The program supports near-patient research with the purpose of improving clinical practice in
osteoporosis. Purely laboratory-based research projects are not eligible.
Proposed projects must fulfil at least one of the following broad objectives:

Evaluate the quality use of medicines in the treatment of osteoporosis

Advance the prevention, diagnosis and/or management of patients with osteoporosis
OR
Such projects may include (but are not limited to):

Development of patient management and practice support systems and tools to improve
operational efficiency and service quality

Investigation of deficiencies or opportunities for improvement in the diagnosis and
management of patients with osteoporosis, and the development of clinical tools or systems
to improve diagnosis and management

Development of patient awareness programs to promote the diagnosis of at-risk populations

Development of services to improve long-term rehabilitation

Investigation of new medicines or interventions for the prevention and/or treatment of
osteoporosis, or research to optimise the effectiveness of existing medicines or
interventions
1
The program will not consider proposals that:


Are wholly or substantially based on laboratory research (including animal research)
Are not primarily concerned with osteoporosis
For guidance, please refer to the Osteoporosis Australia website for summaries of previous projects
funded through this program. We welcome general enquiries concerning project eligibility, but
cannot provide specific guidance on the completion of applications.
SUBMISSION, ASSESSMENT AND AWARD PROCESSES
Submission
The application form must be completed in full. Please answer all questions accurately, observing
word count requirements. Completed applications must be submitted by email by 5:00pm 13th
March 2015. Osteoporosis Australia welcomes preliminary enquiries by telephone (02 951 88140) or
email (research@osteoporosis.org.au). Applications submitted after the closing date will not be
accepted.
Assessment
Applications will be considered by an Expert Panel of the OA-ANZBMS research fund. Eligible
applications will be assessed against the following criteria:
 Service Delivery - potential to deliver improvements in service efficiency or quality of care
 Innovation in prevention, diagnosis, treatment and/or management - potential to deliver
new practices or medicines, or new applications of existing practices or medicines
 Uptake – potential for roll-out of new or improved practices or medicines
 Capacity Building – potential to build new skills in the bone health clinical workforce
In addition, the Expert Panel will assess:
 The novelty and importance of the project
 The feasibility of the project
 The track record of the investigator and his/her capacity to deliver the project outcomes
 Whether the project is likely to achieve its proposed outcomes within the limits of the funding requested
Award
Successful applicant(s) will be advised by telephone within 24 hours of the funding decision being
made. Both successful and unsuccessful applicants will be officially advised by letter within one week
of the funding decision. No further discussion regarding the award outcomes will be entered into.
The award(s) will be formally announced at the Annual Scientific Meeting of the Australian and New
Zealand Bone and Mineral Society in September 2015.
2
Amgen-GSK OA-ANZBMS Clinical Grants Program 2015
APPLICATION FORM
All fields must be completed. Please answer each question accurately, observing word count limits.
Incomplete applications will not be accepted. Ethical and other approvals (where appropriate) must
be submitted with the completed application.
If you have any questions about the submission process, please contact Osteoporosis Australia (02
9518 8140 OR research@osteoporosis.org.au).
Email your completed application to: research@osteoporosis.org.au
Closing date: 17:00 13th March 2015. Applications submitted after the deadline will not be accepted.
DATE
Name and Title
Your details
Current position
Email
Preferred phone number
Medical and/or Research qualifications (list all)
Year that last qualification was awarded
Organisation name and department
Organisation address
Do you have current membership of ANZBMS?
How did you learn about the Amgen-GSK OAANZBMS Clinical Grants Program?
Name and title
Co-investigator details
Organisation and department
Current position
Medical and/or research qualifications
Role in this project
Name and title
Organisation and department
Current position
Medical and/or research qualifications
Role in this project
3
Project details
Project Title
Expected project start date
Expected project duration
Are ethical or other approvals required for this project? Attach copies of relevant documentation.
Please note that project funding will not be released until all approvals and licences have been viewed
by the Expert Panel. Provisional approvals are not acceptable.
Total project budget
Budget
Amount requested from Amgen-GSK OA-ANZBMS
Clinical Grants Program (maximum $40,000)
Other income sources (confirmed and pending)
Project item (only direct project costs will be supported)
1.
2.
3.
4.
5.
6.
4
Cost to Amgen-GSK
OA-ANZBMS fund
Cost to other
funding sources
Lay summary
The lay (non-technical) summary will be used to explain your project to the media and the general
public. The summary should ‘tell the story’ of your project to those with no detailed medical or
scientific knowledge. Avoid technical terms or scientific jargon. If technical terminology is
unavoidable, a brief explanation in plain language should be given.
Lay title of project
What problems does this project address? What impacts do they have on individuals and society?
Maximum 50 words
Describe what you will be doing during your project
Maximum 100 words
In what ways will the outcomes of the project benefit people with osteoporosis?
Maximum 50 words
5
1. What is the overall aim of the project?
Maximum 30 words
2. What unmet clinical need(s) does the project address?
Maximum 300 words
3. List the objectives (expected outputs) of the project.
Maximum 50 words
4. Describe the background to the project, including other research in this area
5. Describe in detail the project design and methodology
6. Please provide a timeline for the project
Deliverable/milestone
Target date
7. Explain the novel aspects of the project.
6
8. How will the project outputs be implemented or developed once the project is
completed? Provide details of further research or implementation activities planned,
including potential sources of funding.
9. Will the project build new skills in the clinical workforce for the benefit of people with
osteoporosis? Please explain.
10. Outline your capacity to complete this project
Describe and provide evidence for your skills and experience in this area.
What skills and experience will your co-investigators contribute?
Will you be drawing on any existing or new collaborations? Please provide details.
What resources will be required to complete this project and how will these be provided or
accessed? (eg., patient cohorts, database access, imaging facilities, pathology services)?
7